Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

Adding Lilly’s biologic Cyramza (ramucirumab) to the chemotherapy paclitaxel significantly boosted median overall survival in patients with advanced gastric (stomach) cancer or gastroesophageal ...

MADRID, Spain—Thanks to Eli Lilly’s phase 3 top-line announcement in May, industry-watchers knew that a Cyramza-chemo had topped a placebo-chemo combo at staving off bladder cancer progression among ...